Abstract Hepatocellular carcinoma (HCC) occurs most commonly secondary to cirrhosis due to chronic hepatitis C or B virus (HCV/HBV) infections. Type I interferon (IFN-) treatment of chronic HCV/HBV infections reduces the incidence of HCC in cirrhotic patients. However, IFN-toxicity limits its tolerability and eYcacy highlighting a need for better therapeutic treatments. 
Introduction
Hepatocellular carcinoma (HCC) is the Wfth most common solid tumor, the third leading cause of cancer related death worldwide, and the second most lethal cancer with the 5-year survival rate below 9% (reviewed in [1] [2] [3] ). Treatment options for HCC are limited due to the low eYciency of existing anticancer drugs against HCC. Due to a lack of biomarkers and screening for HCC, most patients are diagnosed at advanced stages of the disease and are not eligible for surgical tumor resection or orthotopic liver transplantation (OLT) [4] [5] [6] . However, even after resection, the tumor recurrence is about 70% [7] . In patients with unresectable HCC and preserved liver function, transarterial chemoembolization (TACE) prolongs survival. However, TACE is rarely curative and progression-free survival beyond 24 months is infrequent [3, 8] . For patients with advanced disease, systemic chemotherapy is of limited beneWt because of the low responsiveness of HCC to existing anticancer drugs and the fact that about 50% of patients with HCC die secondary to liver failure from cirrhosis [9, 10] .
HCC occurs most frequently in patients with cirrhosis because of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, and alcohol abuse [1, 11] . Because IFN-is used clinically to treat chronic HCV and HBV infection, several studies evaluated the eVect of IFN treatment on the incidence of HCC (reviewed in [1] ). The majority of studies concluded that IFN therapy alone or in combination with ribavirin decreased the incidence of HCC, particularly in patients with sustained virological response [12] [13] [14] [15] . Therefore, IFN alone or in combination with other drugs, can be used as a preventive therapy against the development of HCC in HCV and HBV positive patients. However, numerous adverse eVects limit the overall tolerability of IFN-, particularly in patients with cirrhosis [16, 17] . Because IFN-(or type I IFN) is a pleiotropic cytokine with widespread eVects on nearly all types of cells due to the ubiquitous expression of the IFN-receptor [18] , it is not surprising that most patients develop signiWcant side eVects. Recently, a new type of IFN was discovered and designated IFN-or type III IFN [19, 20] . In addition to its antiviral properties, others and we have demonstrated that IFN-s display potent antitumor activity in murine models of cancer [21] [22] [23] . However, in contrast to IFN-, the activity of IFN-appears to be tissue speciWc [21, 24, 25] , underlining the possibility that IFN-treatment may cause fewer side eVects.
Tissue speciWcity of the IFN-response is determined by the restricted expression of IFN-R1, the unique chain of the IFN-receptor complex that also contains the IL-10R2 chain, which is shared with the IL-10, IL-22, and IL-26 receptor complexes [9, 26] . In contrast, IFN-exerts its biological activities through the heterodimeric type I IFN receptor complex composed of IFN-R1 and IFN-R2 chains [18, 27] . Although IFN-and IFN-engage distinct receptor complexes, they activate similar signaling pathways and induce similar set of genes and, subsequently, biological activities such as antiviral activity and upregulation of MHC class I antigen expression in cells sensitive to both types of IFN (reviewed in [26, 28] ). Within the Jak-STAT (Janus kinases-signal transducers and activators of transcription) signal transduction pathway, both type I and type III IFNs stimulate activation of Jak1 and Tyk2 kinases and several STAT proteins, primarily STAT1 and STAT2 that together with IFN regulatory factor (IRF) 9 form IFN-stimulated regulatory factor 3 (ISGF3) transcription complex [19, 29] . ISGF3 regulates gene transcription by binding to an interferon-stimulated response element (ISRE), whereas activated STAT1 also forms homodimers that bind to an IFN-activation site (GAS) within the promoters of IFN-stimulated genes [30] .
Antiviral studies performed in vitro and in vivo have shown that both IFN-and IFN-contribute to the overall host antiviral defense system [19, 20, [31] [32] [33] [34] . Several studies demonstrated that type III IFNs could inhibit replication of HCV and HBV in vitro [35] [36] [37] [38] . However, in most cases, antiviral potency of IFN-against several viruses, as well as antiproliferative activity, seems to be lower than those of IFN- [19, 20, 31, 36, 39] . In addition, although IFN-and IFN-stimulate similar sets of antiviral genes, the kinetics of IFN--triggered signaling events and induction of target genes were distinct from those triggered by IFN- [36, 40] . Therefore, although signaling and activities induced by IFN-and IFN-seem to be similar, diVerent kinetics, biological potency, and particularly distinct sets of target cells sensitive to IFN-and IFN-suggest that these IFNs have distinct physiological functions.
In the present study, we investigated the role of IFN-in a murine model of hepatoma growth to assess the potential antitumor activity of IFN-and compare it to IFN-. Our results demonstrate that both IFN-and IFN-were potent inducers of innate antitumor responses and displayed comparable antitumor activities in this cancer model.
Materials and methods

Expression plasmids
Expression plasmids pEF-mIFN-2 and pEF-mIFN-R1 were described previously [21] . The intronless mIFN-7 gene was ampliWed by PCR with primers 5Ј-GCGGTACC ATGGCTAGGCTCTGTGCTTTCCTG-3Ј and 5Ј-TCAGG AGAATTCTCTCTACTTTGTC-3Ј and murine genomic C57BL/6 DNA. The resulting PCR product was cloned into a pcDEF3 (pEF) vector [41] with the use of KpnI and EcoRI restriction endonucleases, generating plasmid pEFmIFN-7. The nucleotide sequence of the mIFN-7 gene was determined and found to be identical to GenBank accession number M13710.
Cells and transfection
BALB/c-derived murine hepatocellular carcinoma cell line BNL 1ME A.7R.1 (BNL; ATCC, Manassas, VA, USA), 4T1 mammary gland carcinoma cell line (ATCC), and C57BL6-derived murine melanoma B16 cell line were grown in DMEM supplemented with 10% heat inactivated fetal bovine serum (FBS).
pEF-mIFN-2 and pEF-mIFN-7 plasmids were stably transfected into 10 6 BNL cells with the use of transit-LT1 reagent (Mirus, Madison, WI, USA) and G418-resistant cells were selected (500 g/ml of Geneticin; Invitrogen, Carlsbad, CA, USA). BNL cells were transiently transfected with expression vectors pEF-mIFN-R1 along with coexpression of EGFP using the jetPEITM reagent (Polyplus-transfection Inc., New York, NY, USA).
To assess the proliferation rate, cells were seeded at 0.5 £ 10 5 per well in six-well plates in triplicates, grown at 37°C, and counted at days 1, 2, 3, 4, and 5.
To isolate murine splenocytes, spleen was extracted, placed into RPMI medium with 5% FBS, and minced; large chunks of tissue were removed after gravitational sedimentation, and remaining in suspension splenocytes were pelleted by centrifugation. To isolate murine peripheral blood mononuclear cells (PBMCs), blood, drawn from anesthetized mice by cardiac puncture, underwent red blood cell (RBC) lysis by 10 min incubation with RBC lysis solution (Gentra Systems, Minneapolis, MN, USA); and remaining PBMCs were pelleted.
Flow cytometry
To detect MHC class I expression, cells were treated for 72 h with IFNs or cell-conditioned medium, harvested and incubated with mouse antibody (Ab) against H-2 kb (eBioscience, San Diego, CA, USA), followed by incubation with FITC-goat anti-mouse IgG (Sigma, St. Louis, MO, USA). To identify circulating T regulatory cells, PBMCs were stained Wrst with CD4 APC and CD25 PE (CALTAG Laboratories, Burlingame, CA, USA), Wxed with 2% paraformaldehyde, permeablized with 0.2% Triton-X, and subsequently stained with Foxp3 PE-Cy5 Ab (eBioscience). The isotype-matched rat IgG was used in a control staining. Stained cells were analyzed by Xow cytometry.
Electrophoretic mobility shift assay
To evaluate IFN-induced STAT1 activation, cells were harvested and treated for 15 min with 10 ng/ml of murine IFN-(PeproTech, Rocky Hill, NJ, USA), IFN-(PeproTech) or IFN-(R&D Systems, Minneapolis, MN, USA). Cells were lysed and STAT activation was detected in the cellular extracts by using a P 32 -radiolabled GAS probe in an electrophoretic mobility shift assay (EMSA) as described [21] .
Mice, tumor transplantation, and histological and immunohistochemical analysis of tumor tissue Immunocompetent female BALB/c mice, 6-8 weeks old, were obtained from Jackson Laboratory (Bar Harbor, ME, USA) and maintained in a pathogen-free barrier facility. Mice were injected subcutaneously (s.c.) on the Xank with 10 6 cells in 0.1 ml of PBS. Tumor growth was evaluated by palpation of the injection site every 2 days. Animals with excessive tumor burden (¸1 cm 3 ) were euthanized. For histological evaluation, tumor tissues were extracted from mice with similar tumor size and immediately Wxed in 10% phosphate-buVered formalin. ParaYn-embedded sections were stained with hematoxylin and eosin (H&E) and analyzed by an expert pathologist blinded to treatment group. The mitotic index and lymphocyte inWltration were determined as follows: 15 randomly selected Welds of each slide were examined at high magniWcation [400£ high power Weld (hpf)] and mitotic Wgures (mitoses/hpf) and the rate of lymphocyte inWltration (cells/hpf) were counted.
For immunohistochemical staining of tumors for NK cell inWltration, paraYn-embedded tumor sections were deparaYnized. Samples were subjected to 2100 Retriever (Pickcell Laboratories, Netherlands) in sodium citrate buVer 10 mM pH 6.0, followed by overnight incubation with puriWed anti-mouse CD49b pan-NK cell Ab (1:50; Biolegend, San Diego, CA, USA) at room temperature in a moist chamber and subsequent staining for 2 h at room temperature in a moist chamber with Alexa Fluor 488 goat anti-rat IgM (1:100; Invitrogen). The sections were also stained for nuclei with 40 g/mL 7-aminoactinomycin D (Invitrogen), mounted in Vectashield (Vector Laboratories, Burlingame, CA, USA) and examined in a Zeiss LCM 510 confocal Xuorescent microscope at 250£ magniWcation.
Immunocytotoxicity assays, IL-12, and IFNneutralization, and in vitro NK cell and DC depletion For immunocytotoxicity assays, freshly harvested splenocytes (10 6 cells) were treated in culture with IFN-or IFNin the presence or absence of 10 5 irradiated (7500 Rad) BNL cells for 4 days at 37°C. At day 4, the stimulated splenocytes were isolated and co-cultured with alive BNL or 4T1 target cells (10 5 cells) for 24 h. The number of dead target cells (%) was assessed by FACS analyses of the propidium iodide stained cells in the forward and side scattergated tumor cell population.
In vitro depletion of NK cells was performed by incubating splenocytes for 60 min on ice with 0.25 g of biotinylated monoclonal rat anti-mouse NK antibody (clone DX5; CALTAG Laboratories) or 0.25 g isotype-matched rat IgM. To remove unbound antibody, cells were washed twice with PBS. Pelleted cells were then incubated on ice for 30 min with 30 g of prewashed magnetic Dynabeads M-280 Streptavidin (Dynal Biotech ASA, Oslo, Norway) followed by magnetic pelletation of the cells. Non-pelleted cells were cultured and used in immunocytotoxicity assays.
In vitro depletion of CD11c+ dendritic cells (DCs), mPDCA+ (plasmacytoid DCs), or both populations, were performed on freshly isolated splenocytes. DCs were positively selected by two successive magnetic cell separations (MACS) using CD11c, anti-mPDCA, and Pan DC magnetic MACS microbeads (Miltenyi Biotec, Auburn, CA, USA) followed by magnetic separation with MACS columns and MACS separators according to the manufacturer's protocol.
For IL-12 and IFN-in vitro neutralization, puriWed anti-IL-12p40 antibody (clone C17.8; BioXCell, West Lebanon, NH, USA), puriWed anti-mouse IFN-antibody (clone XMG1.2; eBioscience) or isotype-matched rat IgG was added at a Wnal concentration of 20 g/ml.
IL-12 and IFN-measurement IL-12 and IFN-levels in cultured splenocyte supernatants were measured using MesoScale Discovery (MSD) multiplex kit for mouse pro-inXammatory cytokines (Mesoscale Discovery, Maryland, USA) or mouse IFN-ELISA kit (eBioscience), according to manufacturer's instructions. Sensitivity of MSD for IL-12 and IFN-was 1.2 and 0.3 pg/ml, respectively, and for mouse IFN-ELISA kit, 0.7 pg/ml.
Statistics
The Kaplan-Meier estimator was used to calculate the median survival (Tumor appearance) time and to derive tumor appearance (survival) curves. Statistical analysis was performed using a one-way ANOVA or Mann-Whitney U test. DiVerences were considered to be statistically signiWcant when P value was <0.05.
Results
IFN response in BNL hepatoma cells
The responsiveness of mouse hepatoma BNL cells to three types of IFNs ( , , and ) was determined by measuring STAT1 activation and the ability of IFNs to upregulate the level of MHC class I antigen expression. The formation of STAT1 DNA-binding complexes was strongly induced in response to mIFN-and to a lesser extent in response to mIFN- (Fig. 1a) . Similarly, strong upregulation of MHC class I antigen expression was detected on BNL cells in response to mIFN-and to a lower extent in response to mIFN- (Fig. 1b) . In contrast, treatment of BNL cells with mIFN-failed to induce STAT1 activation or upregulation of MHC class I antigen expression (Fig. 1a, b) . Therefore, in contrast to IFN-and IFN-, IFN-failed to induce a response in BNL cells. However, primary murine hepatocytes not only readily responded to IFN-, but also weakly responded to both IFN-and IFN-as measured by IFNinduced activation of STAT1 DNA-binding complexes (Fig. 1c) , suggesting that hepatocyte-derived BNL cells lost their responsiveness to IFN-. Because the IFN-and IFNreceptors engage similar downstream signal transduction pathways and IFN--induced signaling was intact in BNL cells, resistance to IFN-response could be attributed to the lack of IFN-R1 receptor expression in BNL cells. Indeed, transient expression of intact murine IFN-R1 chain in BNL cells restored STAT1 activation upon treatment with IFN- (Fig. 1d) , indicating that unresponsiveness of BNL cells was due to a deWciency in the IFN-R1 expression.
Constitutive expression of IFN-and IFN-and eVects on tumor growth
In the murine B16 melanoma model, IFN-demonstrated a marked antitumor activity independent of whether B16 cells were sensitive or resistant to IFN-response [21] , implying that IFN-antitumor eVects are mediated by host mechanisms. As previously described [21] , a gene therapy approach was utilized to study IFN-antitumor potential and compare it to that of IFN-in the murine BNL hepatoma model. BNL cells were stably transfected with either pEF-mIFN-2 or pEF-mIFN-7 plasmid, or empty vector. G418-resistant cells were selected, pooled together and designated BNL.IFN-, BNL.IFN-, or BNL.vector cells, respectively.
To assess IFN-and IFN-production, we tested whether conditioned media from BNL.IFNand BNL.IFN-cells can upregulate MHC class I antigen expression in B16 cells that are sensitive to the IFN treatment [21] (Fig. 2) . The expression level of MHC class I antigen was upregulated in B16 cells after treatment with conditioned media from BNL.IFN-or BNL.IFN-cells, but not from control BNL.vector cells (Fig. 2a) . These results demonstrate that BNL.IFN-and BNL.IFN-stable transfectants constitutively secrete mIFN-and mIFN-, respectively. The amounts of IFNs in the conditioned media of BNL.IFN-and BNL.IFN-cells were determined by comparing biological activity of the media with those of recombinant mouse IFN-and IFN-with known concentrations. By measuring IFN-induced MHC class I antigen upregulation in IFN-sensitive B16 melanoma cells, we found that BNL.IFN-and BNL.IFN-cells secrete an average of 1.4 and 1 ng/ml from 0.4 £ 10 6 cells/ml in 24 h, respectively (data not shown).
To determine whether secreted IFNs had an eVect on cell proliferation, we cultured BNL, BNL.vector, BNL.IFN-, and BNL.IFN-cells under identical conditions. Parental BNL cells were also treated with exogenous IFNs. As indicated in Fig. 2b , we did not observe any signiWcant diVerence in the in vitro growth rate between BNL.IFN-, BNL.IFN-, BNL.vector or parental BNL cells. Moreover, treatment with exogenous IFNs did not aVect parental BNL cell proliferation (Fig. 2c) .
Since the constitutive expression of IFN-at the tumor site was found to aVect the tumorigenicity of B16 melanoma cells in vivo [21] , we examined whether similar eVects of IFN-would be displayed in the case of BNL hepatoma. One million parental or modiWed BNL cells were injected subcutaneously into immunocompetent syngeneic BALB/c mice. Mice injected with BNL.vector or parental BNL cells developed tumors in 4-6 weeks, whereas the appearance of BNL.IFN-tumors was signiWcantly delayed (Fig. 2d) To determine whether potential histological modiWcations have occurred in vivo and if they may be associated with the tumor growth delay, tumors were removed from several mice in each experimental group and examined by light microscopy (Fig. 1e) (Fig. 3a) . Preincubation of splenocytes with irradiated BNL cells further augmented killing of BNL cells (Fig. 3a) , suggesting that the presence of tumor antigens enhanced IFN-stimulated cytotoxicity of splenocytes. In combination with antigen, IFN-stimulated higher immunocytotoxicity of splenocytes against tumor cells than IFN-, suggesting that IFN-may be an important player in the antitumor immune response. We next investigated the IFN-induced antitumor mechanisms by assessing the potential modulation of the expression of IL-12 and IFN-, cytokines well known for their role in antitumor immune responses [42, 43] . To test whether IFN-or IFN-have any eVect on IL-12 and/or IFN-secretion, splenocytes were treated with either IFN-or IFN-and the levels of IL-12 and IFN-were assessed. Increased secretion of IL-12 ( Fig. 3b) and IFN-(Fig. 3c) were detected following treatment with IFN-or IFN-. However, the kinetics of secretion and the eVect of IFN-and IFN-were diVerent. The level of IL-12 secretion increased at 24 h of IFN treatment (Fig. 3b) , while the secretion of IFN-was not signiWcantly changed at 24 h, but strongly increased at 96 h of the treatment with IFNs (Fig. 3c ). There is a correlation between higher level of IFN-production (Fig. 3c ) and stronger cytotoxicity (Fig. 3a) observed in the presence of IFN-, suggesting that the immunocytotoxicity induced by IFN-may be mediated by IFN-. Higher levels of IL-12 ( Fig. 3d) and IFN-(Fig. 3e ) secretion were observed after pretreatment of splenocytes with irradiated BNL cells, indicating that the eVect of IFNs, particularly IFN-was enhanced in the presence of tumor antigens. To examine whether IL-12 and IFN-play a role in the IFN-induced immunocytotoxicity, we used neutralizing antibodies against IL-12 and IFN-. Blocking the action of either IL-12 or IFN-inhibited the splenocyte immunotoxicity against BNL cells (Fig. 3f, g ), demonstrating that both cytokines serve as important mediators of IFN--or IFN--induced cytotoxicity of splenocytes against BNL hepatoma cells. To study the in vivo eVect of IFN on immunocytotoxicity, groups of mice (n = 5) were injected with either parental BNL, BNL.IFN-or BNL.IFN-. After 2 weeks, mice were sacriWced, spleens extracted, and splenocytes were immediately co-cultured for 24 h with parental BNL target cells (Fig. 4a) or heterologous 4T1 breast carcinoma target cells (Fig. 4b) . As shown in Fig. 4a, a To determine eVector cells of IFN--induced antitumor immunity, we tested the potential involvement of NK cells. By using an antibody speciWc to NK cells, we depleted NK cells from cultured splenocytes obtained from mice injected with either parental BNL or BNL.IFN-cells and assessed their killing ability against parental BNL cells. Depletion of NK cells from splenocytes of mice injected with BNL.IFNcells resulted in a marked decrease in their cytotoxicity against BNL cells (Fig. 4c) . Therefore, results indicated that NK cells are important mediators of the innate antitumor immunity induced by IFN-.
To determine whether IFN treatment aVects tumor inWltration of NK cells, we performed immunohistochemical . Results in (a) are representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. c NK cells were depleted from splenocytes isolated from mice injected with parental BNL or BNL.IFN-cells with the use of a biotinylated rat monoclonal Ab against NK or with isotype-matched rat IgM as a control. Cytotoxicity of splenocytes against parental BNL cells was evaluated in vitro as described above. Dead parental BNL cell numbers (%) are shown as the mean § SD (n = 3 per data point). Results are representative of three independent experiments. *P < 0.05. d Immunohistochemical staining of CD49b+ NK cells (green Xuorescence) was performed in BNL.parental (left), BNL.IFN-(middle) or BNL.IFN-tumors (right). Samples were examined in a confocal Xuorescent microscope at £250. e NK cells were puriWed from spleen of mice which received BNL.IFN-cells with the use of magnetic beads as described in "Materials and methods". NK cells were treated with IFN-or IFN-(10 ng/ ml) for 15 min, lysed and STAT1 activation was detected in cellular extracts by EMSA. The EMSA is representative of two independent experiments. f PBMCs were isolated from naive mice or mice injected with either parental BNL cells, BNL.IFN-, or BNL.IFN-cells, and the number of circulating CD4+ CD25+ Foxp3+ Tregs in the lymphoid gate population (%) was determined by Xow cytometry and shown as the mean § SD (n = 3 per data point). *P < 0.05 staining for NK cells in the tumor tissue extracted from mice injected with parental or modiWed BNL cells. As indicated in Fig. 4d , in contrast to IFN-, a marked inWltration of NK cells was observed in IFN--producing tumors, suggesting that IFN-may be more potent than IFN-in the recruitment or induction of the proliferation of NK cells at the tumor site. However, when we assessed the response of NK cells to IFNs by measuring IFN-induced STAT1 activation, only IFN-was able to activate STAT1 DNA-binding complexes in NK cells (Fig. 4e) . In contrast, NK cells did not respond directly to IFN- (Fig. 4e) , implying that NK cells were activated by IFN-indirectly. Therefore, the eVect of IFN-on NK cells may be mediated through other molecules such as IL-12 and IFN- (Fig. 3b-g ).
We next asked whether IFN-and IFN-may modulate the number of circulating CD4+ CD25+ Foxp3+ T regulatory cells (Tregs). As shown in Fig. 4f , the amount of Tregs was unchanged in mice inoculated with parental BNL cells in comparison with naive mice. However, a signiWcant decrease in CD4+ CD25+ Foxp3+ Tregs was observed in mice receiving BNL.IFN-, whereas a moderate decrease in Tregs observed in mice receiving BNL.IFN-was not statistically signiWcant (Fig. 4f) . Therefore, antitumor mechanisms activated by IFN-and IFN-may diVer; IFNhad a stronger eVect on Tregs, whereas IFN-increased the number of NK cells at the tumor site.
Involvement of DCs in IFN--induced immunocytotoxicity
IFN-can directly regulate immunomodulatory functions of various immune cells [44, 45] . In contrast, due to restricted pattern of IFN-R1 expression, NK and T cells do not respond directly to IFN-( [21, 24, 46] ; and Fig. 4e ). To investigate whether DCs are involved in mediating eVects of IFN-on NK cells, we Wrst demonstrated that DCs, isolated from mouse splenocytes, are directly responsive to IFN-treatment. IFN-and to a similar extent IFN-were able to induce STAT activation in both myeloid and plasmacytoid DCs (Fig. 5a ). In contrast, splenocytes responded only to IFN-( [21] and Fig. 5a ). We next analyzed the involvement of DCs in the IFN-induced immunocytoxicity by testing the cytotoxic ability of DC-depleted splenocytes against target BNL tumor cells. As shown in Fig. 5b , depletion of DCs caused a decrease in splenocyte cytotoxicity in the presence of IFN-, but not IFN-, demonstrating for the Wrst that DCs are important mediator of IFN--induced antitumor response. The strongest eVect was observed after the depletion of both CD11c+ and PDCA+ DCs (Fig. 5b) . The production of IFN-induced by either IFN-or IFNwas completely abolished after DCs depletion (Fig. 5c) . The suppression of IFN-production in DC-depleted splenocytes inhibited only IFN--but not IFN--induced immunocytotoxicity, demonstrating that splenocytes respond diVerently to IFN-and IFN-.
Discussion
In addition to their potent antiviral activity, type I IFNs are also recognized for their antitumor properties. IFN-is used clinically to treat various malignancies, including hairy cell and myelogenous leukemias, multiple myeloma, lymphomas, renal cell carcinoma, Kaposi sarcoma and metastatic melanoma [18, 47, 48] . In addition, clinical targets of type I IFN therapy include chronic viral infections, particularly HCV and HBV infections. Importantly, chronic HCV and HBV infections are the main cause of HCC [49, 50] . Consequently, preventive treatment against HCC may be highly valuable, particularly in patients with HCV and HBV-associated liver injury. Several studies reported that IFN-therapy decreased the incidence of HCC in patients with HCV or HBV cirrhosis [12] [13] [14] [15] . However, the use of IFN-is limited by numerous severe side eVects including inhibition of hematopoiesis, neuropsychiatric eVects (depression, anxiety) and inXuenza-like symptoms (myalgia, fever, fatigue) [51] [52] [53] [54] . Therefore, there is a great need for alternative biological agents that elicit fewer or less severe side eVects. There is a possibility that type III IFNs or IFN-s [19, 20] may be an attractive treatment compared to type I IFNs. Type III IFNs share biological activities with type I IFNs but their action is tissue-speciWc due to the restricted expression of the IFN-receptor. Therefore, IFN-therapy may cause fewer and/or milder side eVects and improve tolerance of IFN therapy. Indeed, a recently conducted Phase 1b open-label dose-and schedule-escalation study with subcutaneously delivered pegylated IFN-to HCV patients revealed that the treatment was well-tolerated [55] . Interestingly, it was recently demonstrated that a polymorphism near the IFN-3 gene, which seems to aVect IFN-expression levels [56] , was not only correlated and with the spontaneous clearance of HCV [57] , but was also associated with the sustained virologic response in patients with chronic HCV undergoing pegylated IFN-/ribavirin combination therapy [56, 58, 59] .
In the present study, we investigated the antitumor properties of IFN-in comparison with those of IFN-in a murine hepatoma model. Subcutaneously injected hepatoma BNL cells form tumors in syngeneic BALB/c mice (Fig. 2d) . However, injection of BNL cells constitutively producing either IFN-or IFN-resulted in delayed tumor appearance and retarded growth kinetics (Fig. 2d) . Interestingly, although the production of either IFN-or IFN-at the tumor site reduced the tumorigenicity of BNL cells to a similar extent, only IFN-had a direct eVect on BNL cells (Fig. 1a, b) , whereas BNL cells were resistant to IFN-treatment due to the lack of IFN-R1 expression (Fig. 1d) . Nevertheless, none of the IFNs demonstrated an antiproliferative eVect on BNL cells (Fig. 2b, c) , suggesting that both IFNs activate host mechanisms to suppress BNL tumor growth in vivo.
Although histological analysis of the hepatoma tumors did not reveal signiWcant diVerences in the vasculature between the parental tumors and tumors secreting IFNor IFN-, tumors from mice inoculated with BNL.IFNcells had extensive inWltration of immune cells (Fig. 2e) . Immunohistochemical staining of the tumors revealed a marked inWltration of NK cells in IFN--producing tumors (Fig. 4d) , suggesting that IFN-may be more potent than IFN-in the recruitment or induction of the proliferation of NK cells at the tumor site. Moreover, IFN-appeared to be more potent than IFN-in inducing splenocyte cytotoxicity against BNL hepatoma cells (Figs. 3a, 4a ). In addition, treatment of splenocytes with either IFN-or IFNresulted in the secretion of IL-12 and IFN- (Fig. 3b, c ) that was strongly augmented by co-treatment of splenocytes with tumor antigens (Fig. 3d, e) . Moreover, neutralization of either IL-12 or IFN-inhibited IFN-induced splenocyte cytotoxicity (Fig. 3f, g ). Because IL-12 is a major inducer of IFN-production from NK and T cells [60, 61] , it is likely that the eVect of IFN-and IFN-on IFN-secretion is mediated by IL-12. Using antibody-mediated NK cell depletion, we also demonstrated that the antitumor activity induced by IFN-was mediated by NK cells (Fig. 4c) . All these results correlate with recent reports describing the involvement of NK cells in antitumor activities of IFN-in melanoma, colon cancer, and Wbrosarcoma tumor models [22, 23] . Interestingly, NK cells isolated from naive mice or tumor-bearing mice responded well to IFN-treatment, but we were unable to detect responsiveness of NK cells to IFN-treatment (Fig. 4e and data not shown) , demonstrating that NK cells are not a direct target of IFN-, and response. a CD11c+ and mPDCA+ DCs were puriWed from mouse spleens using magnetic MACS microbeads (as described in the "Materials and methods"). DCs and total splenocytes were treated with IFN-or IFN-(10 ng/ml) for 15 min, lysed and STAT1 activation was detected in cellular extracts by EMSA. b In vitro depletion of CD11c+, mPDCA+, or both populations in splenocytes (10 6 ) was performed (as described in the "Materials and methods"). Splenocytes were harvested from naive mice (n = 3) and treated with IFNs in the presence or absence of irradiated (10 5 ) BNL cells (4 day culture). On day 4, splenocytes were collected and co-cultured with fresh (10 5 ) target BNL cells for 24 h. The cells were harvested, stained with propidium iodide, and the amount of dead target BNL tumor cells was assessed by FACS. Dead parental BNL cell numbers (%) are shown as the mean § SD (n = 3 per data point). *P < 0.05, **P < 0.01. c Conditioned media of splenocytes (n = 3) treated with IFNs in (a) were collected after 4 days of treatment and the levels of IFN-in the conditioned media were analyzed. Data are presented as the mean value of triplicate wells § SD suggesting that eVects of IFN-on NK cells are mediated by other IFN--responsive cells such as DCs (Fig. 5a) . Nevertheless, NK cells seem to be important mediators of IFN--induced antitumor responses.
We also observed a strong reduction in circulating CD4+ CD25+ Foxp3+ Tregs only in mice injected with BNL.IFNtumors, whereas a moderate decrease in Tregs observed in mice bearing BNL.IFN-cells was not statistically signiWcant (Fig. 4f) . Although, it has been recently reported that IFN-has the ability to reduce Treg population in mice [62] , it was previously reported that in mixed lymphocyte reaction cultures, IFN--treated DCs speciWcally induced IL-2-dependent proliferation of a CD4+ CD25+ Foxp3+ Tcell subset [63] . In our experimental model, we did not observe statistically signiWcant eVect of IFN-on the number of Tregs (Fig. 4f) . However, we demonstrated that DCs are indeed directly responsive to IFN-treatment (Fig. 5a ) and serve as critical mediators of IFN--and IFN--induced IFN-production from splenocytes (Fig. 5c ). This observation correlates with a role of DC-produced IL-12 as a master regulator of IFN-expression in T and NK cells [60, 63] . Interestingly, depletion of DCs resulted in a signiWcantly decreased cytotoxicity of splenocytes in response to IFN-, but not IFN- (Fig. 5b) . Therefore, although production of IFN-by splenocytes in response to either IFNor IFN-is mediated by DCs, IFN--induced cytotoxicity is unaVected by the depletion of DCs, whereas IFN--induced immunocytotoxicity is mediated by DCs.
In conclusion, this study demonstrated that IFN-has antitumor activity that is comparable to or exceeds that of IFN-in the murine BNL hepatoma model. However, diVerent eVects observed on NK cell recruitment, Treg reduction and the role of DCs in splenocyte cytotoxicity, suggest that IFN-and IFN-activate overlapping but distinct antitumor mechanisms. Therefore, IFN-treatment should be considered as an alternative or additive to currently existing IFN-therapy in the prevention and treatment of liver cancer.
